Zobrazeno 1 - 10
of 91
pro vyhledávání: ''
Autor:
Caicun Zhou, Suresh S. Ramalingam, Ki Hyeong Lee, Kazuhiko Nakagawa, Natasha B. Leighl, Astrid McKeown, Naoyuki Nogami, Thanyanan Reungwetwattana, Johan Vansteenkiste, Eun Kyung Cho, Alessandro Bertolini, Andrew P. Brown, Byoung Chul Cho, Manuel Cobo, Rachel Hodge, Isamu Okamoto, Sabine Bohnet, Yuri Rukazenkov
Publikováno v:
Journal of Clinical Oncology. 36:3290-3297
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non–small-cell lung cancer from the phase III FLAURA study. Pa
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Sarina Anne Piha-Paul, Shari Thomas, Hope S. Rugo, Emilie M.J. van Brummelen, Andrea Varga, Reshma A. Rangwala, Sanatan Saraf, Jean-Sebastien Frenel, Carlos Gomez-Roca, Christophe Le Tourneau, Patrick A. Ott, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology. 35:4035-4041
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from th
Autor:
Li Man, Caijun Yuan, Lizhong Zhou, Jing Shi, Xiujuan Qu, Feng Jin, Fugang Wen, Xiuna Zhang, Ying Luo, Jinglei Qu, Zan Teng, Bo Jin, Tao Sun, Lingyun Zhang, Jian Zhang, Xiuhua Jin, Ping Yu, Mingfang Zhao, Tiejun Chen, Jingyan Wang, Jun Wang, Yuyang Dong, Xiaodong Xie, Ying Chen, Jing Liu, Lingyu Fu, Jingdong Zhang, Yuee Teng, Zhenghua Wang, Yunpeng Liu, Zhitu Zhu, Yuzhi An
Publikováno v:
Journal of Clinical Oncology. 35:3558-3565
Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, p
Autor:
Elizabeth Fox, Yael P. Mosse, Charles G. Minard, Megan S. Lim, Susan M. Blaney, Peter C. Adamson, Brenda J. Weigel, Keith D. Wilner, Stephan D. Voss, Delphine Rolland
Publikováno v:
Journal of Clinical Oncology. 35:3215-3221
Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs). We assessed the activity of the ALK inhibitor crizotinib in patients
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This phase I trial was performed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), preliminary efficacy, and pharmacokinetics (PK) of LY01610, a novel liposome-encapsulated irinotecan, in patients with advanced e
Autor:
Rupert Handgretinger, Phillip Barnette, Benoit Brethon, Chiara Messina, Christian M. Zwaan, Franco Locatelli, Steven G. DuBois, Lia Gore, Peter Bader, Gérard Michel, Kuolung Hu, Carmelo Rizzari, Paul G. Schlegel, James A. Whitlock, Maureen M. O'Brien, Min Zhu, Tanya M. Trippett, Todd M. Cooper, Deepa Bhojwani, Gerhard Zugmaier, Susan R. Rheingold, Arend von Stackelberg, Arndt Borkhardt
Publikováno v:
Journal of Clinical Oncology, 34(36), 4381-4389. American Society of Clinical Oncology
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refracto
Publikováno v:
Journal of Clinical Oncology. 39:83-83
83 Background: Biosimilar products are proven to have no clinically meaningful differences in terms of safety and effectiveness with the reference product, however, to our knowledge, there is limited comparative analysis regarding adverse events for
Autor:
Makoto Nishio, Jie Zhang, Chetachi Emeremni, Myung-Ju Ahn, Lucio Crinò, David R. Spigel, Tony Mok, Toyoaki Hida, Enriqueta Felip, Filippo de Marinis, Massimiliano Quadrigli, Giorgio V. Scagliotti, Alice T. Shaw, Fabrice Branle, Heather A. Wakelee, Harry J.M. Groen
Publikováno v:
Journal of Clinical Oncology, 34(24), 2866-2878. AMER SOC CLINICAL ONCOLOGY
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and with or without prior therapy with an inhibitor of the ALK protein. Data are pre
Autor:
Yunfei Wang, Beth A. Hellerstedt, Steven Papish, Lina Asmar, Frankie A. Holmes, Joyce O'Shaughnessy, Shrinivas M. Diggikar, Praveen K. Reddy, Regina Resta, Susan Peck, Lea Krekow, Patricia S. Fox, Rufus P. Collea, Svetislava J. Vukelja
Publikováno v:
Journal of Clinical Oncology. 34:1594-1600
Purpose This prospective study assessed the impact of 2 years of aromatase inhibitor (AI) therapy on the incidence of ovarian function recovery (OFR) in women age 40 to 49 with estrogen receptor–positive breast cancer who were premenopausal at diag